Inotiv Acquires Protypia to Expand Protein/Peptide Bioanalytical Capabilities
July 7, 2022
Inotiv, Inc. completed the acquisition of Nashville-based Protypia, Inc., a protein/peptide bioanalytical company, for approximately $11.0 million in a combination of cash, Inotiv common shares and promissory notes. The deal adds quantitative tissue-based large-molecule mass spectrometry capabilities to Inotiv's bioanalytical offerings to support immuno-oncology, cell and gene therapy, and other drug development programs.
- Buyers
- Inotiv, Inc.
- Targets
- Protypia, Inc.
- Industry
- Healthcare Services
- Location
- Tennessee, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Inotiv Acquires HistoTox Labs
April 13, 2021
Healthcare Services
Inotiv, Inc. has entered into an agreement to purchase substantially all assets of HistoTox Labs, a histopathology contract research organization, for $22.0 million in cash. The acquisition (subject to financing and customary closing conditions) expands Inotiv's pathology and histology capabilities, adds a Boulder, Colorado facility with digital pathology and immunohistochemistry capabilities, and is expected to retain all HistoTox employees.
-
Invaio Sciences Acquires Peptyde Bio
December 7, 2023
Biotechnology
Invaio Sciences has acquired Peptyde Bio, a Danforth Technology Company spinout that discovers and designs antimicrobial peptides for crop protection. The deal brings Peptyde Bio’s peptide discovery platform and IP into Invaio’s AI-enabled discovery engine and biological delivery systems to accelerate nature-positive crop protection solutions.
-
Aditxt Acquires Ignite Proteomics for $36 Million
March 19, 2026
Healthcare Services
Aditxt announced the $36 million acquisition of Ignite Proteomics, a commercial-stage precision oncology company. The deal was structured through the issuance of 36,000 shares of Aditxt’s newly designated Series A-2 convertible preferred stock, and Ignite will operate as a subsidiary within Aditxt’s oncology initiatives.
-
Johnson & Johnson to Acquire Proteologix, Inc.
May 16, 2024
Biotechnology
Johnson & Johnson entered into a definitive agreement to acquire privately held biotechnology company Proteologix for $850 million in cash, with potential additional milestone payments. The deal is expected to close mid-year 2024 subject to antitrust clearance and customary closing conditions, expanding J&J’s bispecific antibody pipeline for immune-mediated diseases including atopic dermatitis and asthma.
-
NanoImaging Services Acquires Proteos
January 5, 2025
Biotechnology
NanoImaging Services (NIS), a cryo-electron microscopy services provider backed by Ampersand Capital Partners, has acquired Proteos, Inc., a Kalamazoo-based CRO specializing in recombinant protein and antibody production. The add-on acquisition integrates Proteos’ protein production capabilities with NIS’s cryo-EM services to create an end-to-end offering for structure-based drug discovery and protein production workflows.
-
Boehringer Ingelheim Acquires Nerio Therapeutics
August 6, 2024
Biotechnology
Boehringer Ingelheim agreed to acquire Nerio Therapeutics, a San Diego-based preclinical biotech focused on PTPN2/N1 phosphatase inhibitors for immuno-oncology, for up to $1.3 billion. Nerio was invested/incubated by Viva BioInnovator and backed by a syndicate including Avalon Ventures; the deal is intended to accelerate development of Nerio’s preclinical program as a cornerstone of Boehringer’s immuno-oncology portfolio.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.